Tag archive for ‘Opdivo misses endpoint in Checkpoint-26’
Bristol-Myers Squibb: Checkmate-026 Trial Fails to Reach Primary Endpoint (BMY, $62.85); A Buying Opportunity
Perspective Bristol-Myers Squibb Company announced today that Opdivo had failed to reach its primary endpoint of progression free survival in the CheckMate -026 trial in first line non-small cell lung cancer. This was an open-label, study that randomized 541 patients to receive either Opdivo as monotherapy or investigator’s choice of chemotherapy. Patients enrolled in the […]